These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt, with results 2005-002901-22 A phase I-IIa clinical study on the investigational anticancer drug J1 in patients with advanced cancer. A prospective, single armed, open label, dose-finding phase I-IIa study. 2011-09-23 not-yet-due
Reported results 2012-004315-31 An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients with Relapsed and/or Relapsed-Refractory Multiple Myeloma 2019-07-09 due-trials
Reported results Terminated 2016-000965-21 A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab. E... 2021-11-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2016-003517-95 A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Le... 2023-02-03 bad-data
Reported results 2017-002120-24 An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple ... 2022-02-02 due-trials
Reported results Terminated 2018-000478-31 A Study of the Pharmacokinetics of Melphalan During Treatment with Melflufen and Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma and Impaired Renal Function 2021-12-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-002761-19 An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy 2022-01-11 bad-data
Reported results 2019-002161-36 A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in combination with Daratumumab Compared with Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma 2022-02-07 due-trials
Reported results 2019-004127-21 A randomized, two-period, cross-over, Phase 2 study, comparing the pharmacokinetics, and assessing safety and tolerability of peripheral and central intravenous administration of melflufen in patients... 2022-01-10 due-trials